Cspc Pharmaceutical Group Stock Price To Earnings To Growth
| CHJTF Stock | USD 0.67 0.16 19.28% |
CSPC Pharmaceutical Group fundamentals help investors to digest information that contributes to CSPC Pharmaceutical's financial success or failures. It also enables traders to predict the movement of CSPC Pink Sheet. The fundamental analysis module provides a way to measure CSPC Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CSPC Pharmaceutical pink sheet.
CSPC |
CSPC Pharmaceutical Group Company Price To Earnings To Growth Analysis
CSPC Pharmaceutical's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Current CSPC Pharmaceutical Price To Earnings To Growth | 2.55 X |
Most of CSPC Pharmaceutical's fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CSPC Pharmaceutical Group is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, CSPC Pharmaceutical Group has a Price To Earnings To Growth of 2.5472 times. This is 258.76% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The price to earnings to growth for all United States stocks is 47.91% higher than that of the company.
CSPC Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CSPC Pharmaceutical's direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of CSPC Pharmaceutical could also be used in its relative valuation, which is a method of valuing CSPC Pharmaceutical by comparing valuation metrics of similar companies.CSPC Pharmaceutical is currently under evaluation in price to earnings to growth category among its peers.
CSPC Fundamentals
| Return On Equity | 0.2 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.22 % | |||
| Current Valuation | 11.19 B | |||
| Shares Outstanding | 11.93 B | |||
| Shares Owned By Insiders | 29.56 % | |||
| Shares Owned By Institutions | 34.01 % | |||
| Price To Earning | 14.83 X | |||
| Price To Book | 3.41 X | |||
| Price To Sales | 0.45 X | |||
| Revenue | 27.87 B | |||
| Gross Profit | 21.14 B | |||
| EBITDA | 7.72 B | |||
| Net Income | 5.61 B | |||
| Cash And Equivalents | 13.97 B | |||
| Cash Per Share | 1.17 X | |||
| Total Debt | 682.56 M | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 2.70 X | |||
| Book Value Per Share | 2.35 X | |||
| Cash Flow From Operations | 4.64 B | |||
| Earnings Per Share | 0.07 X | |||
| Price To Earnings To Growth | 2.55 X | |||
| Number Of Employees | 24.75 K | |||
| Beta | 0.76 | |||
| Market Capitalization | 13.6 B | |||
| Total Asset | 34.74 B | |||
| Z Score | 11.4 | |||
| Annual Yield | 0.02 % | |||
| Net Asset | 34.74 B | |||
| Last Dividend Paid | 0.24 |
About CSPC Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CSPC Pharmaceutical Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CSPC Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CSPC Pharmaceutical Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in CSPC Pink Sheet
CSPC Pharmaceutical financial ratios help investors to determine whether CSPC Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CSPC with respect to the benefits of owning CSPC Pharmaceutical security.